Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscape
Cash runway extended to 2025, enabling initial clinical data readouts for both ONCT-808, ROR1-tageting CAR T for patients with aggressive lymphomas, and ONCT-534, novel AR inhibitor for patients with resistant mCRPC
Management to host webcast today at 5:00 pm ET
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.